List of Excipients in Branded Drug AQNEURSA

AQNEURSA Excipient Strategy and Commercial Opportunities

Last updated: August 8, 2026

AQNEURSA is an oral levacetylleucine product approved in the United States for neurological manifestations of Niemann-Pick disease type C, a rare lysosomal storage disorder. Its commercial opportunity is driven primarily by orphan-disease pricing, chronic treatment, and a small but identifiable patient population. Excipient strategy should prioritize palatability, dose uniformity, low water activity, administration flexibility, and protection of the single-dose sachet format.

The product’s excipient platform is commercially important because AQNEURSA is administered as oral granules rather than a conventional tablet or capsule. That format supports pediatric and adult use, but it also creates formulation, packaging, taste, and substitution risks for potential competitors.

What is AQNEURSA and which excipients does it contain?

AQNEURSA contains levacetylleucine, a modified amino-acid derivative, in 4-gram oral granules supplied in unit-dose packets. The FDA-approved labeling identifies mannitol, sucralose, and natural flavor among the inactive ingredients. The granules are intended to be mixed with water or administered with soft food before oral use. [1]

AQNEURSA formulation profile

Attribute	AQNEURSA profile
Active ingredient	Levacetylleucine
Dosage form	Oral granules
Strength	4 g per packet
Administration	Mixed with water or soft food
Patient population	Adults and pediatric patients with NPC
Key excipient functions	Bulking, sweetness, palatability, powder handling
Commercial format	Single-dose sachet or packet
Regulatory pathway	FDA approval under the orphan-drug framework
Primary therapeutic area	Niemann-Pick disease type C neurological manifestations

Mannitol likely provides bulk and contributes to mouthfeel. Sucralose addresses the bitter or acidic taste profile that can arise from a high-load amino-acid-related active ingredient. Natural flavor supports acceptability, especially in children and patients who require long-term treatment.

The formulation has a high active load. At 4 grams per packet, excipients cannot materially increase volume without making the product more difficult to administer. This favors low-level, high-impact excipients rather than a complex multiparticulate system.

Why is the AQNEURSA excipient strategy commercially important?

The excipient strategy addresses four commercial constraints:

1. A large oral dose must be delivered in a manageable format.
2. NPC treatment is chronic, so adherence depends on tolerability.
3. The patient population includes children and patients with neurological impairment.
4. A generic or follow-on product must reproduce a user experience, not only the active ingredient strength.

Taste is likely the most important patient-facing issue. Levacetylleucine is administered in gram quantities, making complete taste masking difficult with conventional coating technology. A simple sweetened and flavored powder may be more practical than a coated tablet or capsule because it avoids swallowing barriers and supports administration with food or water.

What excipient functions matter most?

Formulation need	Relevant excipient or technology	Commercial rationale
Bulk and powder flow	Mannitol, lactose alternatives, polyols	Supports packet filling and dose uniformity
Sweetness	Sucralose, acesulfame potassium, steviol glycosides	Reduces bitterness and improves adherence
Flavor	Strawberry, berry, citrus, or neutral flavor	Improves pediatric acceptability
Moisture control	Low-moisture excipient system, high-barrier laminate	Protects flow, stability, and packet integrity
Dispersibility	Granulation and particle-size control	Reduces clumping when mixed with water
Dose uniformity	Controlled blending and granule engineering	Important for unit-dose manufacturing
Food compatibility	Rapid wetting and sedimentation control	Supports administration with soft food

What formulation patents could protect AQNEURSA?

The strongest formulation opportunities are likely to concern the finished dosage form rather than the basic active ingredient. Potential claim areas include:

• Levacetylleucine granules with defined particle-size distributions.
• Unit-dose sachets containing a specified active-to-excipient ratio.
• Flavor and sweetener systems that improve acceptability without increasing moisture uptake.
• Granules that disperse in water or soft food within a defined period.
• Low-water-activity compositions that preserve chemical and physical stability.
• Packaging systems that protect the product from humidity.
• Administration methods for patients unable to swallow conventional dosage forms.
• Specific combinations of levacetylleucine, mannitol, sucralose, and flavor.

A formulation patent would need to show more than the use of a routine sweetener or flavor. Patent value would increase if the sponsor can demonstrate a measurable technical effect, such as improved stability, reduced agglomeration, better dose recovery from the packet, faster dispersion, or superior blinded palatability scores.

How strong is the excipient patent estate likely to be?

The excipient estate is potentially moderate rather than automatically strong. The active ingredient is administered at a high dose, and many conventional excipient combinations would be predictable to a formulation scientist. Broad claims covering "levacetylleucine with a sweetener" could face written-description, enablement, or obviousness challenges.

Stronger protection would come from narrow, reproducible parameters, including:

• Defined water activity.
• Defined residual moisture.
• Specific granule size ranges.
• Controlled dissolution or dispersion times.
• Demonstrated stability under accelerated conditions.
• Particular packaging and desiccant configurations.
• Clinical or human-factor evidence showing improved adherence.

A commercial competitor may be able to avoid a narrow formulation patent by changing the flavor, sweetener, carrier, granulation process, or package while maintaining the same active dose.

When does AQNEURSA lose exclusivity?

AQNEURSA received FDA orphan-drug approval for Niemann-Pick disease type C. Orphan-drug exclusivity generally prevents FDA approval of the same drug for the same disease or condition for seven years from approval, subject to statutory exceptions. The approval date was September 24, 2024. [2]

AQNEURSA exclusivity timeline

Milestone	Date or status
FDA approval	September 24, 2024
Orphan-drug exclusivity	Generally runs through September 24, 2031
Product form	Oral granules
Generic pathway	Potential ANDA or 505(b)(2), depending on product and regulatory approach
Patent-based blocking	Must be assessed separately from orphan exclusivity
Pediatric market	Included in the approved population, subject to label dosing

Orphan exclusivity is not the same as patent protection. It does not prevent all competing products. A different drug, a different indication, or a product that qualifies under an orphan-exclusivity exception may enter earlier. Patent claims, regulatory exclusivity, and commercial barriers must therefore be analyzed separately.

The precise patent expiration timetable depends on the patents listed in the FDA Orange Book and any applicable patent-term adjustment or extension. Orange Book listings should be reviewed against the current Drugs@FDA record and patent certifications filed by applicants. [3]

What is the Orange Book status of AQNEURSA?

AQNEURSA is an FDA-approved small-molecule product and therefore may have Orange Book-listed patents if the sponsor submitted eligible patent information. The Orange Book may list patents directed to:

• The drug substance.
• The approved formulation.
• The method of use.
• The dosage form or route of administration.

An Orange Book patent can trigger a Paragraph IV certification from an ANDA applicant. A Paragraph IV notice can initiate patent litigation and create a statutory 30-month stay of approval if the sponsor files suit within the applicable period. [4]

What Paragraph IV challenges could affect AQNEURSA?

A generic applicant could challenge AQNEURSA through:

1. A Paragraph IV certification against listed patents.
2. A Paragraph III certification accepting delayed approval until patent expiration.
3. A section viii statement seeking approval for non-patented uses.
4. A 505(b)(2) application relying partly on FDA findings for levacetylleucine.

The most vulnerable claims would likely be broad method-of-use claims covering treatment of NPC neurological symptoms if prior art discloses levacetylleucine or related compounds for neurological disease. Formulation claims could be challenged as obvious if they rely on conventional powder excipients without a demonstrated technical advantage.

A section viii strategy could become relevant if a listed patent covers only a particular NPC manifestation or dosing regimen. That pathway would depend on the scope of the approved label and the exact wording of the patent claims.

What generic entry risks exist for AQNEURSA?

Generic entry risk is limited in the near term because the product has a rare-disease indication, a high-dose oral powder format, and a small prescriber base. The risk increases after orphan exclusivity expires, especially if the active ingredient is available from multiple suppliers and the formulation does not have durable patent protection.

Key barriers to generic entry

Clinical and regulatory barrier

NPC is a rare disease with a small, specialized patient population. A generic applicant may need to establish bioequivalence using a design that accounts for the granule dosage form, food administration, and possible dispersion in water or soft food.

Manufacturing barrier

The active ingredient represents most of the packet mass. Manufacturing challenges may include:

• Uniform distribution of a high-dose active ingredient.
• Control of powder segregation.
• Consistent packet fill weight.
• Prevention of moisture-related clumping.
• Flavor homogeneity.
• Reliable dispersion after mixing.

Commercial barrier

A competitor would need access to NPC specialists, diagnostic centers, patient-support programs, reimbursement infrastructure, and disease education. These barriers may be more significant than the cost of excipients.

Substitution barrier

A tablet or capsule may be technically feasible but commercially inferior if patients have dysphagia, pediatric dosing needs, or established packet-based administration routines. A competing product that preserves the same granule format has a stronger substitution position.

What commercial opportunities exist for AQNEURSA excipients?

The largest commercial opportunity is not a single novel excipient. It is the development of a differentiated delivery platform for high-dose rare-disease powders.

Pediatric-friendly delivery

Flavor systems, low-dust granules, and rapid dispersion can improve administration in children. A supplier could offer a validated excipient premix tailored to levacetylleucine, reducing formulation-development time for sponsors and follow-on manufacturers.

Alternative flavor systems

The approved product uses natural flavor. Opportunities include:

• Neutral flavor for adults.
• Berry or citrus profiles for children.
• Reduced-sweetness formulations for patients with taste fatigue.
• Flavor systems compatible with soft foods.
• Excipient systems that minimize aftertaste.

Flavor switching may support lifecycle management, but it is unlikely to create strong market exclusivity by itself.

Moisture-protective packaging

High-barrier sachets, desiccant-integrated cartons, and improved heat-seal systems could create value if they extend shelf life or reduce packet failures. Packaging patents may be more defensible than broad sweetener claims when supported by stability data.

Ready-to-use liquid or semi-solid formats

A sponsor could pursue an oral suspension, gel, or premeasured liquid. These formats may improve administration but introduce new risks:

• Chemical stability in water.
• Microbial control.
• Preservative tolerability.
• Higher shipping weight.
• More complex packaging.
• Potentially shorter shelf life after opening.

A liquid product could receive separate formulation claims and potentially support a 505(b)(2) lifecycle strategy, but development cost would be materially higher than for a powder line extension.

Hospital and specialty-pharmacy packaging

Unit-dose packets can be adapted for:

• Caregiver administration.
• Specialty-pharmacy dispensing.
• Home nursing.
• Travel packs.
• Adherence tracking.
• Temperature and humidity monitoring.

The commercial value of these formats depends on payer coverage and patient-support contracts rather than excipient innovation alone.

How does AQNEURSA compare with competing NPC treatments?

AQNEURSA competes in a narrow therapeutic market that includes substrate-reduction and symptom-directed approaches. The most relevant comparison is with miglustat, an oral therapy used in some jurisdictions for NPC and other lysosomal storage disorders, although regulatory status and labeling differ by country. [5]

Factor	AQNEURSA	Miglustat
Active ingredient	Levacetylleucine	Miglustat
Product type	Oral granules	Oral capsules
Primary differentiation	High-dose granule delivery and NPC neurological indication	Established oral small-molecule lysosomal therapy
Pediatric administration	Powder may be advantageous	Capsule swallowing may be limiting
Excipient opportunity	Taste, dispersion, moisture control	Capsule shell and powder-fill optimization
Commercial model	Orphan specialty product	Rare-disease specialty product
Generic risk	Tied to orphan exclusivity, patents, and powder manufacturing	More mature product and potential generic competition

AQNEURSA’s granule format may provide a practical advantage for patients who cannot swallow capsules. Its disadvantage is the formulation burden associated with taste, dose size, and packet handling.

What licensing opportunities exist around AQNEURSA excipients?

Licensing opportunities may arise in four areas:

1. A sponsor licenses a taste-masking or flavor technology for a lifecycle product.
2. An excipient manufacturer supplies a qualified premix under a preferred-vendor agreement.
3. A contract development and manufacturing organization licenses a sachet-filling process.
4. A follow-on applicant licenses manufacturing know-how to reproduce granule properties without copying protected claims.

The most valuable deal terms would likely concern exclusivity by territory, supply guarantees, change-control rights, regulatory support, and ownership of process improvements. A commodity excipient supply agreement would have limited strategic value unless the supplier provides a qualified grade with a documented manufacturing advantage.

Publicly disclosed AQNEURSA transaction terms and excipient-specific licensing arrangements are limited. The commercial rights and development history are associated with IntraBio and its levacetylleucine program, while Ipsen has announced a strategic transaction involving IntraBio assets. [6] Any excipient licensing analysis should distinguish product ownership, commercialization rights, and manufacturing supply rights.

What patent litigation could affect AQNEURSA?

The principal litigation risk will emerge when an ANDA or 505(b)(2) applicant challenges Orange Book patents. The relevant disputes could involve:

• Validity of method-of-use claims.
• Obviousness of the granule formulation.
• Written description of pediatric dosing.
• Infringement by alternative flavor or sweetener systems.
• Whether a competitor’s product falls within a claimed sachet composition.
• Whether an applicant can use a section viii statement to omit a patented indication.

Before the orphan-exclusivity period ends, patent litigation may have limited immediate commercial effect unless the challenger seeks an entry date after exclusivity but before patent expiration. Settlement agreements could include licensed entry dates, authorized-generic rights, or restrictions on formulation features. No settlement should be assumed without a filed court record or regulatory disclosure.

What revenue exposure does AQNEURSA create?

AQNEURSA’s revenue exposure is concentrated rather than broad. The product depends on:

• The diagnosed NPC population.
• Treatment initiation and persistence.
• Reimbursement approval.
• Specialist adoption.
• Geographic expansion.
• Continued orphan-drug pricing.
• Protection against a lower-cost granule competitor.

For a rare-disease product, excipient improvements can affect revenue through persistence and dispensing efficiency even when they do not expand the addressable population. A more palatable product can reduce discontinuation. A more stable packet can lower waste. A liquid or pediatric-friendly presentation can improve diagnosis-to-treatment conversion.

Revenue risk rises materially if a competitor offers the same active ingredient in a lower-cost, easy-to-administer sachet after orphan exclusivity expires. The most defensible commercial position combines formulation patents with manufacturing know-how, patient-support services, and specialty-pharmacy execution.

Key Takeaways

• AQNEURSA is a 4-gram levacetylleucine oral-granule product for NPC.
• Its key excipient functions are bulk, sweetness, flavor, powder flow, and dispersion.
• The product’s high active load makes palatability and moisture control central formulation issues.
• Orphan-drug exclusivity generally runs through September 24, 2031.
• Formulation patents are more likely to protect defined granule, stability, packaging, or administration parameters than routine sweetener combinations.
• Generic entry risk is constrained by the rare-disease market, but it increases after orphan exclusivity and any enforceable patent barriers expire.
• The strongest commercial opportunities are pediatric delivery, alternative flavor systems, moisture-protective packaging, liquid or semi-solid lifecycle products, and qualified excipient premixes.
• AQNEURSA’s competitive position depends on formulation usability and specialty-market execution as much as on active-ingredient protection.

FAQs

Can AQNEURSA be reformulated as a tablet?

A tablet is technically possible, but the 4-gram dose would create substantial size and swallowing challenges. A tablet would need to demonstrate comparable administration, stability, and patient acceptability.

Which excipient is most important for AQNEURSA taste?

Sucralose and flavor are the primary palatability tools identified in the FDA label. Their effectiveness depends on the active ingredient’s concentration, particle size, dispersion behavior, and aftertaste.

Could a competitor use a different flavor and avoid an AQNEURSA formulation patent?

Possibly. A different flavor alone may avoid a narrow flavor claim, but it would not avoid broader claims covering the active-to-excipient ratio, granule properties, dispersion, moisture content, or packet configuration.

Is a biosimilar pathway available for AQNEURSA?

No. AQNEURSA contains a small-molecule active ingredient, so the relevant follow-on pathways are generally an ANDA or a 505(b)(2) application rather than a biosimilar application.

What is the most valuable lifecycle-management product for AQNEURSA?

A stable, palatable pediatric liquid or semi-solid formulation could have the highest lifecycle value, but it would require more development and manufacturing controls than the existing dry granule format.

References

1. U.S. Food and Drug Administration. (2024). AQNEURSA (levacetylleucine) oral granules: Prescribing information.
2. U.S. Food and Drug Administration. (2024). FDA approves first treatment for neurological manifestations of Niemann-Pick disease type C.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2024). Hatch-Waxman amendments and abbreviated new drug applications.
5. European Medicines Agency. (2024). Zavesca: Product information.
6. Ipsen. (2024). Ipsen to acquire IntraBio and its late-stage rare disease portfolio.